Share capital
(excluding share premium):
Voting Rights
Total number of voting rights (denominator)
(all relating to ordinary shares)
Total number of securities carrying voting rights
(all ordinary shares)
Total number of securities carrying voting rights not yet issued
Transparency Declarations
Act of May 2nd 2007 – Royal Decree of February 14th, 2008
Pursuant to Article 13 of the company’s Articles of Association and the legal requirements enacted in the Belgian Act of May 2nd 2007 on the disclosure of major shareholdings in listed companies, the applicable major shareholding notification thresholds are set at 3%, 5% and 7,5% and multiples of 5% of the company’s total number of securities with voting rights issued.
Major Shareholding Notifications should be filed with the Financial Services and Markets Authority (FSMA), as well as with Hyloris Pharmaceuticals.
The FSMA advises to notify them electronically by e-mail on the following account: trp.fin@fsma.be , as well as by fax on the number +32 2 220 59 12.
The company advises to file the notification to the attention of its Legal Department by e-mail: investorrelations@hyloris.com.
For more detailed information on the compliance with the applicable disclosure obligations, please note that the FSMA has made available on its website (www.fsma.be/en/Supervision/fm/gv/ah/circah/ov.aspx) a Form TR-1 BE and an Information Guide concerning Transparency Legislation and Forms.
SHAREHOLDER | DATE | DOWNLOAD |
---|---|---|
Stijn Van Rompay | 31.07.20 | |
Stijn Van Rompay | 02.07.20 | |
Thomas Jacobsen | 02.07.20 | |
Scorpiaux BV | 02.07.20 | |
Nick Reunbrouck | 02.07.20 | |
Pieter Van Rompay | 02.07.20 | |
Saffelberg Investment NV | 02.07.20 |
Completed and signed forms should be sent to investorrelations@hyloris.com